ArticleMicrobial cell factories2005
Ensuring safety of DNA vaccines.
Article in Microbial cell factories, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 86 citations in OpenAlex.
- Article
- Multivariate modular metabolic engineering and medium optimization for vitamin BSynthetic and systems biotechnology · 2024Article
- Salmonella Typhimurium expressing chromosomally integrated Schistosoma mansoni Cathepsin B protects against schistosomiasis in mice.NPJ vaccines · 2023Article
- Article
- Vaccines against SARS-CoV-2 variants and future pandemics.Expert review of vaccines · 2022Review
- Process intensification at the expression system level for the production of 1-phosphate aldolase in antibiotic-free E. coli fed-batch cultures.Journal of industrial microbiology & biotechnology · 2022Article
- 3D-Printed Drug Capture Materials Based on Genomic DNA Coatings.ACS applied materials & interfaces · 2021Article
- Gut Immune System and the Implications of Oral-Administered Immunoprophylaxis in Finfish Aquaculture.Frontiers in immunology · 2021Review
- Rolling circle amplification: A high fidelity and efficient alternative to plasmid preparation for the rescue of infectious clones.Virology · 2020Article
- Recombinant PAL/PilE/FlaA DNA vaccine provides protective immunity against Legionella pneumophila in BALB/c mice.BMC biotechnology · 2020Article
- Vaccination against the digestive enzyme Cathepsin B using a YS1646 Salmonella enterica Typhimurium vector provides almost complete protection against Schistosoma mansoni challenge in a mouse model.PLoS neglected tropical diseases · 2019Article
- Review
- Live Bacterial Vectors-A Promising DNA Vaccine Delivery System.Medical sciences (Basel, Switzerland) · 2018Review
- Efficacy and Safety of the Immunization with DNA for Alzheimer's Disease in Animal Models: A Systematic Review from Literature.Journal of Alzheimer's disease reports · 2017Article
- Improved Specificity of Gene Electrotransfer to Skin Using pDNA Under the Control of Collagen Tissue-Specific Promoter.The Journal of membrane biology · 2015Article
- Surface display of an anti-DEC-205 single chain Fv fragment in Lactobacillus plantarum increases internalization and plasmid transfer to dendritic cells in vitro and in vivo.Microbial cell factories · 2015Article
- The murine intravaginal HSV-2 challenge model for investigation of DNA vaccines.Methods in molecular biology (Clifton, N.J.) · 2014Article
- Article
- Comparison of immune response generated against Japanese encephalitis virus envelope protein expressed by DNA vaccines under macrophage associated versus ubiquitous expression promoters.Virology journal · 2011Article
- Comparative analysis of macrophage associated vectors for use in genetic vaccine.Genetic vaccines and therapy · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 1990 a new approach for vaccination was invented involving injection of plasmid DNA in vivo, which elicits an immune response to the encoded protein. DNA vaccination can overcome most disadvantages of conventional vaccine strategies and has potential for vaccines of the future. However, today 15 years on, a commercial product still has not reached the market. One possible explanation could be the technique's failure to induce an efficient immune response in humans, but safety may also be a fundamental issue. This review focuses on the safety of the genetic elements of DNA vaccines and on the safety of the microbial host for the production of plasmid DNA. We also propose candidates for the vaccine's genetic elements and for its microbial production host that can heighten the vaccine's safety and facilitate its entry to the market.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.